HRP20210459T1 - Supstituirani derivati oksopiridina - Google Patents
Supstituirani derivati oksopiridina Download PDFInfo
- Publication number
- HRP20210459T1 HRP20210459T1 HRP20210459TT HRP20210459T HRP20210459T1 HR P20210459 T1 HRP20210459 T1 HR P20210459T1 HR P20210459T T HRP20210459T T HR P20210459TT HR P20210459 T HRP20210459 T HR P20210459T HR P20210459 T1 HRP20210459 T1 HR P20210459T1
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- solvates
- image
- compound
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15176099 | 2015-07-09 | ||
| EP16157350 | 2016-02-25 | ||
| EP16734672.5A EP3319956B1 (en) | 2015-07-09 | 2016-07-05 | Substituted oxopyridine derivatives |
| PCT/EP2016/065787 WO2017005725A1 (en) | 2015-07-09 | 2016-07-05 | Substituted oxopyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210459T1 true HRP20210459T1 (hr) | 2021-05-14 |
Family
ID=56345141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210459TT HRP20210459T1 (hr) | 2015-07-09 | 2016-07-05 | Supstituirani derivati oksopiridina |
Country Status (39)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3197896B1 (de) * | 2014-09-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| US20190119213A1 (en) * | 2015-03-19 | 2019-04-25 | Bayer Pharma Aktiengesellschaft | Oxo-pyridine-derivatives as factor xia inhibitors for the treatment of thrombosis |
| JO3703B1 (ar) * | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| US10633375B2 (en) | 2016-08-31 | 2020-04-28 | Jinagsu Hengrui Medicine Co., Ltd | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
| ES2920449T3 (es) * | 2018-03-15 | 2022-08-04 | Bayer Ag | Proceso de preparación de dos derivados de 4-{[(2s)-2-{4-[5-cloro-2-(1H-1,2,3-triazol-1-il)fenil]-5-metoxi-2-oxopiridin-1(2H)-il}butanoil]amino}-2-fluorobenzamida |
| DK3774796T3 (da) | 2018-04-10 | 2022-07-18 | Bayer Pharma AG | Et substitueret oxopyridinderivat |
| JP2021529201A (ja) | 2018-07-02 | 2021-10-28 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． | オキシピリジンアミド誘導体の結晶形およびその調製方法 |
| AR115870A1 (es) | 2018-07-31 | 2021-03-10 | Sumitomo Chemical Co | MÉTODO PARA CONTROLAR EL HONGO DE LA ROYA DE LA SOJA QUE TIENE RESISTENCIA AL INHIBIDOR DE SITIO Qₒ |
| CN113166099A (zh) * | 2018-12-17 | 2021-07-23 | 拜耳公司 | 用于治疗和/或预防血栓形成性或血栓栓塞性疾病和/或血栓形成性或血栓栓塞性并发症的取代的氧代吡啶衍生物 |
| CA3124296A1 (en) | 2018-12-21 | 2020-06-25 | Bayer Aktiengesellschaft | Substituted oxopyridine derivatives |
| MX2021007508A (es) | 2018-12-21 | 2021-08-05 | Bayer Ag | Derivados de oxopiridina sustituidos. |
| EP4036087A4 (en) * | 2019-09-27 | 2023-09-20 | Shenzhen Salubris Pharmaceuticals Co. Ltd | Fxia inhibitors and preparation method therefor and pharmaceutical use thereof |
| EP4215525A4 (en) | 2020-09-17 | 2024-08-21 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Piperazine derivative, preparation method therefor and use thereof |
| CN114621140B (zh) * | 2020-12-10 | 2023-08-11 | 中国科学院上海药物研究所 | 芳基二氟乙酰胺化合物及其制备方法和用途 |
| CA3212644A1 (en) * | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide |
| WO2022189279A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Crystalline forms of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-5 dibenzenaheptaphane-74-carboxamide |
| WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
| US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| CN113666826B (zh) * | 2021-07-30 | 2024-03-26 | 五邑大学 | 一种芳基或杂芳基甲氧基化反应的方法 |
| CN116199672A (zh) * | 2021-11-30 | 2023-06-02 | 成都泰和伟业生物科技有限公司 | 一种嘧啶酰胺类衍生物及其制备方法和用途 |
| WO2023174399A1 (zh) * | 2022-03-18 | 2023-09-21 | 苏州晶云药物科技股份有限公司 | 取代的氧代吡啶类衍生物的晶型及其制备方法 |
| CN116262734B (zh) * | 2022-11-18 | 2025-05-13 | 成都施贝康生物医药科技有限公司 | 氧代吡啶类化合物及其制备方法和用途 |
| CN116262735B (zh) * | 2022-11-18 | 2025-05-13 | 成都施贝康生物医药科技有限公司 | 新型氧代吡啶类化合物及其制备方法和用途 |
| CN116262740A (zh) * | 2022-11-18 | 2023-06-16 | 成都施贝康生物医药科技有限公司 | 新型氧代吡啶类化合物及其制备方法和用途 |
| CN116082303B (zh) * | 2022-12-21 | 2025-02-25 | 成都施贝康生物医药科技有限公司 | 新型氧代吡啶类化合物及其中间体和应用 |
| CN116262736B (zh) * | 2022-12-26 | 2025-05-13 | 成都施贝康生物医药科技有限公司 | 新型氧代吡啶类化合物及其制备方法和用途 |
| WO2024200335A1 (en) | 2023-03-31 | 2024-10-03 | Bayer Aktiengesellschaft | Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32 h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| CN116535392B (zh) * | 2023-06-26 | 2023-09-05 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物的制备方法及中间体和应用 |
| CN116621742B (zh) * | 2023-06-09 | 2025-05-06 | 成都施贝康生物医药科技有限公司 | 氧代吡啶类化合物的新型制备方法及关键中间体 |
| CN116751136B (zh) * | 2023-06-21 | 2025-08-29 | 成都施贝康生物医药科技有限公司 | 氧代吡啶类化合物的新型制备方法及关键中间体 |
| CN116621728B (zh) * | 2023-06-09 | 2025-07-29 | 成都施贝康生物医药科技有限公司 | 氧代吡啶类化合物的新型制备方法及关键中间体 |
| WO2024251276A1 (zh) * | 2023-06-09 | 2024-12-12 | 成都施贝康生物医药科技有限公司 | 氧代吡啶类化合物的新型制备方法及关键中间体和应用 |
| CN116730861A (zh) * | 2023-06-21 | 2023-09-12 | 成都施贝康生物医药科技有限公司 | 氧代吡啶类化合物的新型制备方法及关键中间体 |
| CN116874387B (zh) * | 2023-06-21 | 2025-08-26 | 成都施贝康生物医药科技有限公司 | 氧代吡啶类化合物的新型制备方法及关键中间体 |
| CN117164564B (zh) * | 2023-09-07 | 2025-07-08 | 成都施贝康生物医药科技有限公司 | 氧代哒嗪类化合物及其制备方法和用途 |
| CN117164566B (zh) * | 2023-09-07 | 2025-06-06 | 成都施贝康生物医药科技有限公司 | 一种氧代哒嗪类化合物及其制备方法和用途 |
| CN117164563B (zh) * | 2023-09-07 | 2025-06-10 | 成都施贝康生物医药科技有限公司 | 氧代嘧啶类化合物及其制备方法和用途 |
| CN117164561A (zh) * | 2023-09-07 | 2023-12-05 | 成都施贝康生物医药科技有限公司 | 一种氧代嘧啶类化合物及其制备方法和用途 |
| CN117164562B (zh) * | 2023-09-07 | 2025-06-13 | 成都施贝康生物医药科技有限公司 | 一种氧代哒嗪类化合物及其制备方法和用途 |
| CN117164565B (zh) * | 2023-09-07 | 2025-05-27 | 成都施贝康生物医药科技有限公司 | 一种氧代嘧啶类化合物及其制备方法和用途 |
| CN117186073B (zh) * | 2023-09-08 | 2025-06-06 | 成都施贝康生物医药科技有限公司 | 氧代嘧啶类化合物及其制备方法和用途 |
| CN118894814B (zh) * | 2024-07-15 | 2025-09-12 | 上海康鹏科技股份有限公司 | 1-(2-溴-4-氯苯基)-4-(三氟甲基)-1h-1，2，3-三唑的制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
| US6642252B2 (en) | 2000-11-07 | 2003-11-04 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| EP1526131A1 (en) | 2003-10-22 | 2005-04-27 | Graffinity Pharmaceuticals Aktiengesellschaft | Aminoalkyl-pyrazinones and -pyridones as thrombin inhibitors |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| TW200813017A (en) | 2006-05-05 | 2008-03-16 | Millennium Pharm Inc | Factor XA inhibitors |
| WO2008079787A2 (en) | 2006-12-20 | 2008-07-03 | Takeda San Diego, Inc. | Glucokinase activators |
| UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| EP2766347B1 (en) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| ES2765891T3 (es) | 2011-12-21 | 2020-06-11 | Ono Pharmaceutical Co | Derivados de piridinona y pirimidinona como inhibidores del factor XIa |
| GB2497806A (en) | 2011-12-21 | 2013-06-26 | Ono Pharmaceutical Co | Pyridinone and pyrimidinone derivatives as factor XIa inhibitors |
| BR112015002081A2 (pt) * | 2012-08-03 | 2017-07-04 | Bristol Myers Squibb Co | di-hidropiridona p1 como inibidores de fator xia |
| US9617259B2 (en) | 2013-03-14 | 2017-04-11 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| WO2014160592A2 (en) * | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| TWI633089B (zh) | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| JP6410819B2 (ja) | 2013-07-23 | 2018-10-24 | バイエル ファーマ アクチエンゲゼルシャフト | 置換オキソピリジン誘導体および第ＸＩａ因子／血漿としてのその使用 |
| WO2015063093A1 (de) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| UY35971A (es) | 2014-01-31 | 2015-07-31 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Macrociclos con grupos p2? aromáticos como inhibidores del factor xia |
| EP3138839B1 (en) | 2014-02-14 | 2020-10-28 | Sichuan Haisco Pharmaceutical Co., Ltd. | Pyridone or pyrimidone derivative, preparation method therefor and application thereof |
| WO2016046157A1 (de) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate |
| EP3197896B1 (de) | 2014-09-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| EP3197889B1 (de) | 2014-09-24 | 2018-08-01 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
| US10414731B2 (en) | 2014-09-24 | 2019-09-17 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| US20170298052A1 (en) | 2014-09-24 | 2017-10-19 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
| ES2722425T3 (es) | 2014-09-24 | 2019-08-12 | Bayer Pharma AG | (2H)-2-Oxopiridinas como inhibidores del factor XIa para el tratamiento de enfermedades trombóticas |
| JO3703B1 (ar) * | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| KR102697816B1 (ko) * | 2015-08-05 | 2024-08-21 | 브리스톨-마이어스 스큅 컴퍼니 | 신규 치환된 글리신 유도된 fxia 억제제 |
-
2016
- 2016-07-03 JO JOP/2016/0136A patent/JO3703B1/ar active
- 2016-07-05 KR KR1020187003576A patent/KR102596164B1/ko active Active
- 2016-07-05 US US15/742,063 patent/US10421742B2/en active Active
- 2016-07-05 MX MX2018000076A patent/MX377903B/es unknown
- 2016-07-05 TN TNP/2018/000011A patent/TN2018000011A1/en unknown
- 2016-07-05 HR HRP20210459TT patent/HRP20210459T1/hr unknown
- 2016-07-05 DK DK16734672.5T patent/DK3319956T3/da active
- 2016-07-05 EA EA201890111A patent/EA036208B1/ru not_active IP Right Cessation
- 2016-07-05 LT LTEP16734672.5T patent/LT3319956T/lt unknown
- 2016-07-05 JP JP2017568177A patent/JP6871180B2/ja active Active
- 2016-07-05 ES ES16734672T patent/ES2856554T3/es active Active
- 2016-07-05 EP EP16734672.5A patent/EP3319956B1/en active Active
- 2016-07-05 PL PL16734672T patent/PL3319956T3/pl unknown
- 2016-07-05 GE GEAP201614692A patent/GEP20197046B/en unknown
- 2016-07-05 UA UAA201801270A patent/UA122341C2/uk unknown
- 2016-07-05 MA MA42376A patent/MA42376B1/fr unknown
- 2016-07-05 RS RS20210338A patent/RS61584B1/sr unknown
- 2016-07-05 HU HUE16734672A patent/HUE053552T2/hu unknown
- 2016-07-05 WO PCT/EP2016/065787 patent/WO2017005725A1/en not_active Ceased
- 2016-07-05 AU AU2016289746A patent/AU2016289746B2/en active Active
- 2016-07-05 SI SI201631060T patent/SI3319956T1/sl unknown
- 2016-07-05 CU CU2018000001A patent/CU24512B1/es unknown
- 2016-07-05 MY MYPI2018700053A patent/MY196640A/en unknown
- 2016-07-05 CR CR20180017A patent/CR20180017A/es unknown
- 2016-07-05 CA CA2990901A patent/CA2990901C/en active Active
- 2016-07-05 CN CN201680052335.5A patent/CN108026072B/zh active Active
- 2016-07-05 CN CN202110557164.4A patent/CN113292539B/zh active Active
- 2016-07-05 PE PE2018000035A patent/PE20180538A1/es unknown
- 2016-07-07 TW TW105121492A patent/TWI717367B/zh active
- 2016-07-08 UY UY0001036780A patent/UY36780A/es active IP Right Grant
-
2017
- 2017-12-25 IL IL256556A patent/IL256556B/en active IP Right Grant
-
2018
- 2018-01-04 NI NI201800001A patent/NI201800001A/es unknown
- 2018-01-05 CL CL2018000039A patent/CL2018000039A1/es unknown
- 2018-01-05 DO DO2018000004A patent/DOP2018000004A/es unknown
- 2018-01-05 PH PH12018500057A patent/PH12018500057A1/en unknown
- 2018-01-08 SV SV2018005610A patent/SV2018005610A/es unknown
- 2018-01-08 EC ECIEPI20181308A patent/ECSP18001308A/es unknown
- 2018-01-09 CO CONC2018/0000113A patent/CO2018000113A2/es unknown
- 2018-02-08 ZA ZA2018/00826A patent/ZA201800826B/en unknown
-
2019
- 2019-08-08 US US16/535,120 patent/US11180471B2/en active Active
-
2021
- 2021-03-26 CY CY20211100269T patent/CY1123996T1/el unknown
- 2021-10-18 US US17/504,243 patent/US20230024752A1/en not_active Abandoned
-
2025
- 2025-05-27 US US19/219,838 patent/US20250282748A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210459T1 (hr) | Supstituirani derivati oksopiridina | |
| ME02664B (me) | Derivati premeštanja piridina u toku transfekcije inhibitora (ret) kinaze | |
| JP2018519323A5 (enExample) | ||
| HRP20241768T1 (hr) | Heterociklički spoj | |
| NZ627750A (en) | Carbamate compounds and of making and using same | |
| HRP20210447T1 (hr) | Piridinski spoj | |
| PE20130405A1 (es) | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso | |
| HRP20161547T1 (hr) | Derivati 5-fluor-n-(piridin-2-il)piridin-2-amina koji sadrže sulfoksiminsku skupinu | |
| PE20161416A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| NZ622769A (en) | Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection | |
| JP2014037426A5 (enExample) | ||
| ME03723B (me) | 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori | |
| PH12018501236A1 (en) | Pharmaceutical composition comprising a potent inhibitor urat1 | |
| HRP20170695T1 (hr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka | |
| HRP20150049T1 (hr) | Derivati oksazolil-metiletera kao agonisti alx-receptora | |
| HRP20141199T1 (hr) | Kombinacija od spoja glyt1 s antipsihoticima | |
| MX2021002258A (es) | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. | |
| EA201691402A1 (ru) | Фармацевтический препарат, содержащий соединение пиридиламиноуксусной кислоты | |
| WO2020247298A3 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
| HRP20161237T1 (hr) | Antimalarijski agensi | |
| NZ611529A (en) | Glucagon receptor modulators | |
| RU2019111873A (ru) | Новые антимикробные соединения, их применение для лечения инфекций млекопитающих и новый метаболический механизм | |
| CY1124383T1 (el) | Προληψη ή αγωγη παθησης ουρικου οξεος ή ποδαγρας | |
| HRP20120257T1 (hr) | Antagonisti receptora 5-ht7 |